CagriSema通过减少能量摄入和维持能量消耗来促使大鼠体重减轻。
CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.
作者信息
Jacobsen Julie Mie, Halling Jens Frey, Blom Ida, Moreno Martinez Jaime, Hald Bjørn, Pedersen Kent, Fels Johannes Josef, Snitker Søren, Secher Anna, Lundh Sofia, le Roux Carel W, Raun Kirsten, Reitman Marc L, Kuhre Rune Ehrenreich
机构信息
Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
出版信息
Nat Metab. 2025 Jul 8. doi: 10.1038/s42255-025-01324-8.
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake. By contrast, pair-feeding causes less-pronounced weight loss, while weight matching requires a 51% decrease in food intake. Therefore, approximately one-third of CagriSema's weight loss efficacy arises from an effect on energy expenditure, the blunting of metabolic adaptation, which contributes to the successful treatment of obesity.
CagriSema是一种用于体重管理的胰淀素（卡格列汀）和胰高血糖素样肽-1（司美格鲁肽）类似物的组合。在此，我们表明CagriSema可减弱大鼠的代谢适应性。通过量化CagriSema对大鼠能量摄入和消耗的作用，我们观察到体重减轻了12%，食物摄入量减少了39%。相比之下，配对喂养导致的体重减轻不那么明显，而体重匹配则需要食物摄入量减少51%。因此，CagriSema约三分之一的减肥效果源于对能量消耗的影响，即代谢适应性的减弱，这有助于肥胖症的成功治疗。
Zotero 插件